Navigation Links
Abbott Announces Earnings Guidance for 2009
Date:1/12/2009

ABBOTT PARK, Ill., Jan. 12 /PRNewswire-FirstCall/ -- Abbott today is announcing its full-year earnings-per-share guidance for 2009 and confirming its previously issued 2008 earnings-per-share guidance of $3.31 to $3.33, excluding specified items. For 2009, the company expects earnings per share of $3.65 to $3.70 under Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. The midpoint of this 2009 guidance reflects double-digit growth over the midpoint of 2008 earnings-per-share guidance.

Abbott's 2009 outlook includes the acquisition of Advanced Medical Optics (AMO) as announced today (see separate news release). Abbott expects the AMO transaction to be neutral to ongoing earnings per share in 2009 and accretive in 2010, both before one-time transaction-related costs, which will be provided at a later date.

Further details regarding Abbott's earnings-per-share guidance for 2009 will be provided on the company's fourth-quarter 2008 earnings conference call scheduled for Jan. 21, 2009. Including net specified items, Abbott forecasts earnings per share for the full-year 2008 under GAAP of $3.04 to $3.06. Abbott forecasts net specified items for the full-year 2008 of $0.27 per share, primarily associated with previously announced cost reduction initiatives, acquired in-process R&D, and litigation settlements. These items were partially offset primarily by previously announced one-time gains from the sale of Abbott's spine business, conclusion of the TAP joint venture, and favorable tax settlements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

              Private Securities Litigation Reform Act of 1995 -
               A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. We caution that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2007, and in Item 1A, "Risk Factors," to Abbott's Quarterly Report on Securities and Exchange Commission Form 10-Q for the quarters ended June 30, 2008, and September 30, 2008, and are incorporated by reference.


'/>"/>
SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences
2. Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
3. Abbotts XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
4. Abbott Hosts Conference Call for Third-Quarter Earnings
5. Abbott to Present at UBS Best of Americas Investment Conference
6. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
7. Abbott and AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR(R)
8. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. Abbott Invests Additional $20M in Isis Subsidiary Ibis Biosciences
11. Abbott to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016 - And ... and Producers of Those Competitor Biologics  - ... Activities and Prospects ,  Who are the ... And what are their sales potentials? Discover, in our ... results, trends, opportunities and revenue forecasting. ...
(Date:5/2/2016)... 2016 Q BioMed Inc. (QBIO), ... Mannin Research Inc. will be attending the Association for ... from May 1-5, 2016 in Seattle Washington ... its vendors and research partners. The meeting provides organizations ... other collaborative opportunities for the MAN-01 program for treatment ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design ... the bioLogic team explored how bacterial properties can be applied to fabric and formed ... bacteria, which move in response to humidity change. The team harvested Natto cells and ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John Kelley, ... Mr. Kelley, a recognized leader and mentor in the Denver area business community, ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):